Patient Square Launched by Ex-KKR Pro

Patient Square Capital has been launched in Menlo Park, California by Jim Momtazee and Maria Walker.

Patient Square will invest across the health care industry with a specific interest in technology-enabled services, biopharmaceuticals, pharmaceuticals, medical devices, diagnostics, providers, digital health, and consumer health.

Mr. Momtazee, the firm’s managing partner, is a 21-year veteran of KKR, where he helped form its health care industry group in 2001 and subsequently led the group for over 10 years. Some of Mr. Momtazee’s transactions while at KKR include Jazz Pharmaceuticals (2004); Hospital Corporation of America (2006), a $33 billion transaction which at the time was the largest cash buyout in history; PRA Health Sciences (2013); and BridgeBio Pharma (2016).

“In an industry as critical, complex, and capital intensive as health care, there exists a need for a specialized investment firm with substantial scale that is built for and focused every day on health,” said Mr. Momtazee. “Successful health care organizations relentlessly focus on the patient. A successful and enduring health care investment firm must do the same. Patient Square is the combination of a patient approach to investing and a patient-centered orientation.”

Ms. Walker, a partner and the CFO of Patient Square, has extensive experience across private equity and health care, including 17 years at KPMG where she served as a senior partner and a global lead in its private equity practice. She was with KPMG from 1993 to 2000 and again from 2008 to 2018.

“Focus and experience will drive excellence in everything we do,” said Ms. Walker. “Patient Square Capital, as a dedicated health care firm, will make outstanding investments through its depth of relationships, insight, and resources, while maintaining the highest standards of communication and transparency to investors.”

Ms. Walker was most recently the founder and CEO of Recuerdo Therapeutics, a biotechnology startup focused on the postponement of Alzheimer’s disease.

Private Equity Professional | August 18, 2020

Print Friendly, PDF & Email